Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Xtandi
Xtandi
Astellas and Pfizer's Xtandi Meets Primary Endpoint in Ph III Trial of Metastatic Prostate Cancer
CP Wire
Thu, 12/20/18 - 10:27 am
Astellas
Pfizer
Xtandi
prostate cancer
metastatic prostate cancer
Astellas and Pfizer's Xtandi Meets Primary Endpoint in Ph III Trial of Metastatic Prostate Cancer
Thu, 12/20/18 - 10:19 am
Astellas
Pfizer
Xtandi
prostate cancer
metastatic prostate cancer
Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214
BioCentury
Tue, 11/6/18 - 11:35 am
Pfizer
Nektar Therapeutics
NKTR-214
Xtandi
Talzenna
Bavencio
prostate cancer
Pharma/Biotech Stocks to Watch This Prostate Cancer Month
Yahoo/Zacks.com
Sun, 09/16/18 - 02:16 pm
prostate cancer
JNJ
Zytiga
Erleada
Pfizer
Astellas
Xtandi
AbbVie
Lupron
Endocyte
Lu-PSMA-617
Pfizer, Astellas revise two cancer drug trial protocols to speed up results
Yahoo/Reuters
Wed, 08/22/18 - 06:05 pm
Pfizer
Astellas
clinical trials
Xtandi
prostate cancer
Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population
Yahoo/Zacks.com
Mon, 07/16/18 - 09:40 am
Pfizer
FDA
Astellas
Xtandi
prostate cancer
Can This Pharma's $14 Billion Bet Succeed?
Motley Fool
Tue, 06/12/18 - 09:39 am
Pfizer
M&A
Medivation
Xtandi
talazoparib
Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook
Fierce Pharma
Fri, 04/6/18 - 11:49 am
Merck
Pfizer
immuno-oncology
M&A
Keytruda
Prevnar
Ibrance
Xeljanz
Xtandi
How Pfizer Plans to Move Into the Big Leagues for Cancer Treatment
Motley Fool
Thu, 03/15/18 - 09:55 am
cancer
oncology
Pfizer
Ibrance
breast cancer
Xtandi
prostate cancer
Bavencio
bladder cancer
Merkel cell carcinoma
lorlatinib
metastatic non-small cell lung cancer
talazoparib
metastatic breast cancer
Pfizer, Astellas peg Xtandi expansion on PROSPER data
Biopharma Dive
Mon, 02/5/18 - 07:09 pm
Pfizer
Astellas
Xtandi
prostate cancer
Patent setback could sting J&J prostate cancer franchise
Biopharma Dive
Fri, 01/19/18 - 11:11 am
patents
JNJ
prostate cancer
Zytiga
Xtandi
Astellas
With Pfizer in hot pursuit, J&J loses a critical patent fight as it scrambles for a new prostate cancer drug OK
Endpoints
Thu, 01/18/18 - 10:00 am
Pfizer
JNJ
patents
Zytiga
Xtandi
prostate cancer
apalutamide
New PhIII data in hand, Pfizer, Astellas hustle ahead in bid to expand US market for Xtandi
Endpoints
Thu, 09/14/17 - 10:27 am
Pfizer
Astellas
clinical trials
Xtandi
prostate cancer
Astellas, Pfizer scrap a PhIII breast cancer study using Xtandi; New $30M fund will back Israeli biotech startups
Endpoints
Sat, 05/20/17 - 12:50 pm
Astellas
Pfizer
breast cancer
clinical trials
Xtandi
Israel
biotech
Here's Why the Best Is Yet to Come for Pfizer Inc.
Motley Fool
Mon, 05/15/17 - 08:59 am
Pfizer
Eucrisa
Xtandi
Inflectra
With Pfizer’s Xtandi sales slowing, analysts question $14B Medivation price
Fierce Pharma
Wed, 05/3/17 - 02:15 pm
Pfizer
Xtandi
Medivation
Astellas inks biomarker deal to pinpoint Xtandi patients
BioPharma Dive
Sat, 02/4/17 - 09:59 am
Astellas
Xtandi
biomarkers
patients
tumor profiles
The 3 Biggest Risks for Pfizer in 2017
Motley Fool
Tue, 12/27/16 - 10:29 am
Pfizer
Xtandi
competition
patents
Lyrica
Celebrex
Pfizer's Xtandi fails in progression trial vs J&J's Zytiga
Yahoo/Reuters
Thu, 12/15/16 - 10:10 am
Xtandi
Pfizer
JNJ
Zytiga
prostate cancer
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
Tue, 10/4/16 - 10:07 am
FDA
clinical trials
Exelixis
cabozantinib
Cobimetinib
Celldex Therapeutics
CDX-011
Cerulean Pharma
CRLX101
Medivation
Xtandi
Palatin
bermelanotide
Rexahn
RX-3117
Anthera Pharmaceuticals
Pages
« first
‹ previous
1
2
3
4
5
6
next ›
last »